Pulmonary fibrosis patients have long suffered through side effects from their drugs. That could change with the potential for new inhaled versions in clinical trials.
GLP-1 agonists have transformed the treatment of type 2 diabetes and obesity, but they come with side effects. Physicians say the benefits outweigh the risks.